Canada
· Delayed Price · Currency is CAD Telo Genomics Company Description
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions primarily in Canada.
Its TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive of genomic instability to identify specific disease mechanisms, predict disease risks, and determine effective treatments.
Its lead product is TeloView-SMM (Smoldering Multiple Myeloma) for SMM patients with high risk of transition to multiple myeloma (MM).
The company also develops TeloView NDMM that predicts newly diagnosed MM patients who may relapse on 1st line therapy; TeloMRD-D Enumaeration that identifies and enumerates MRD cells in post-transplant patients; and TeloViewNG-MRD (Minimal Residual Disease) Profiling for genomic instability profiling of MRD detected cells in post-transplant patients.
It has a collaboration agreement with the Mayo Clinic. Telo Genomics Corp. is headquartered in Toronto, Canada.
| Country | Canada |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Sabine Mai |
Contact Details
Address: MaRS Centre Toronto, M5G 1L7 Canada | |
| Phone | 416 673 8487 |
| Website | telodx.com |
Stock Details
| Ticker Symbol | TELO |
| Exchange | TSX Venture Exchange |
| Fiscal Year | July - June |
| Reporting Currency | CAD |
| ISIN Number | CA87975M2085 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sabine Mai Ph.D. | Founder, Interim Chief Executive Officer, Chair of the Clinical and Scientific Advisory Board and Director |
| Guido Baechler | Executive Chairman |
| Christopher Ross CPA, CGA | Chief Financial Officer |
| Dr. Mark Stene M.B.A., Ph.D. | Head of Laboratory Operations |